<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495092</url>
  </required_header>
  <id_info>
    <org_study_id>CAF-DTX-1</org_study_id>
    <secondary_id>INT/71525/2003</secondary_id>
    <nct_id>NCT00495092</nct_id>
  </id_info>
  <brief_title>Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients</brief_title>
  <official_title>Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy of caffeine compared to placebo in
      detoxifying cocaine dependent patients. Caffeine potentiation with biperiden will be also
      studied.

      108 with cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t.i.d.)
      plus biperidene (8 mg b.i.d.) or caffeine (300 - 1200 mg t.i.d.) with placebo or placebo
      during 6 months.

      Primary efficacy outcomes will be 1) patient comfort assessed with abstinence symptomatology,
      craving for cocaine and mental status during detoxifying period, 2) study retention and 3)
      cocaine use.

      Brain dopamine system will be assessed thru IBZM-SPECT and the apomorphine test.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1) comfort with cocaine detox defined as cocaine abstinence symptoms, cocaine craving, depressive symptoms and anxiety symptoms 2) study retention and 3) cocaine use.</measure>
    <time_frame>12-14 days for primary otcome num 1 and 23 weeks for num 2 and 3.</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Cocaine Related Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study arm will receive caffeine+placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this study arm will receive Caffeine+Biperiden</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>this study arm will receive placebo+placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biperiden</intervention_name>
    <description>Biperiden 2-4 mg/d p.o.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo + Placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of intranasal cocaine dependence, according to DSM-IV-TR criteria

          -  age between 18 and 60 years

          -  current cocaine use, confirmed by a positive urine drug screen for cocaine the week
             prior to admission.

          -  demonstrated capacity to grant informed consent and sign the pertinent informed
             consent form.

          -  place of residence compatible with attendance at the centre.

          -  for women, willingness to use effective contraceptive measures during the study.

        Exclusion Criteria:

          -  diagnosis of a severe medical disorder that could interfere with the study

          -  presence of an organic pathology for which methylxanthines or biperidene, iodine or
             apomorphine administration is contraindicated

          -  serum liver transaminase levels 3 times higher than normal values

          -  pregnancy and breast-feeding

          -  neuroleptic medication treatment in the past 6 weeks

          -  current treatment, or anticipation that the patient may need to initiate treatment
             during the study with drugs that may interact with study medication.

          -  current diagnosis of a major mental disorder.

          -  awareness of a situation that could prevent the patient's participation in the study
             (e.g. serving a sentence)

          -  current participation in another research project.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miquel Casas, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Vall d'Hebron Barcelona, Catalonia, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2007</study_first_submitted>
  <study_first_submitted_qc>June 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <last_update_submitted>February 29, 2012</last_update_submitted>
  <last_update_submitted_qc>February 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2012</last_update_posted>
  <responsible_party>
    <name_title>Miguel Casas Brugu√©</name_title>
    <organization>Servei de Psiquiatria. Hospital Universitari Vall d'Hebron</organization>
  </responsible_party>
  <keyword>cocaine dependence</keyword>
  <keyword>cocaine use</keyword>
  <keyword>cocaine craving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Biperiden</mesh_term>
    <mesh_term>Biperiden lactate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

